title: [Efficacy of chemotherapy combined with bevacizumab for unresectable advanced or recurrent colorectal cancer].
abstract: Systemic treatment for metastatic or advanced colorectal cancer(mCRC)has remarkably progressed during recent years. All previously untreated mCRC patients at our institution between November, 2007 and June, 2010 were retrospectively evaluated. Of 72 patients, 39 were treated with chemotherapy alone, and 33 were treated with chemotherapy plus bevacizumab(BV). The median progression-free survival(mPFS)was 329 days in the group given chemotherapy plus BV, compared with 209 days in the group given chemotherapy alone(p=0. 0189). In sub-group analysis of those treated with chemotherapy plus BV, mPFS between 70 y/o<and<70 y/o was not different(368 vs 306 days, respectively; p=0. 7872). The relative dose intensity of oxaliplatin(L-OHP)was 80% in the group with FOLFOX+BV(n=15), and 92% with XELOX+BV(n=8). Chemotherapy with BV for previously untreated mCRC was well tolerated and effective.
authors.affiliation: Dept. of Surgery, Japanese Red Cross Society, Japan.
authors.forename: Takanori
authors.initials: T
authors.lastname: Watanabe
authors.forename: Noriyuki
authors.initials: N
authors.lastname: Nishiwaki
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Kajiwara
authors.forename: Takuya
authors.initials: T
authors.lastname: Okamoto
authors.forename: Manabu
authors.initials: M
authors.lastname: Miyamoto
authors.forename: Takeshi
authors.initials: T
authors.lastname: Kohjima
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Watanabe
authors.forename: Keisuke
authors.initials: K
authors.lastname: Yoshino
authors.forename: Takashi
authors.initials: T
authors.lastname: Kawai
authors.forename: Keisuke
authors.initials: K
authors.lastname: Toda
authors.forename: Tetsuji
authors.initials: T
authors.lastname: Nobuhisa
authors.forename: Yoshikatsu
authors.initials: Y
authors.lastname: Endo
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Matsumoto
authors.forename: Naoki
authors.initials: N
authors.lastname: Watanabe
authors.forename: Kyouhei
authors.initials: K
authors.lastname: Kai
authors.forename: Shizo
authors.initials: S
authors.lastname: Sato
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012008:Recurrence
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab